Soleno Therapeutics
CompanyUnited States
Soleno Therapeutics develops one asset. Mostly small molecule acting on ABCC8; based in the United States.
- 1
- Asset
- Furthest stage
- Not known
- 1
- Trial
- 1
- Signal
Pipeline
1Opens ATP-sensitive potassium channels to suppress hypothalamic appetite signaling and reduce hyperphagia.
Stage not known, Small molecule, ABCC8
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies2
Papers
Short-Term Reproducibility of i3C Risk Score in Predicting Cardiac Events in Young People
ADA Scientific Sessions 2025 abstract, 13 Jun 2025